MHAA4549A

DRUG4 trials

Sponsors

Genentech, Inc.

Conditions

Healthy VolunteerInfluenzaInfluenza A

Phase 1

A Study of MHAA4549A to Assess Safety And Pharmacokinetics in Healthy Volunteers

CompletedNCT01877785

Genentech, Inc.Healthy Volunteer

Start: 2013-07-31End: 2013-11-30Updated: 2016-11-02

A Study of High Dose MHAA4549A in Healthy Volunteers

CompletedNCT02284607

Genentech, Inc.Healthy Volunteer

Start: 2014-11-03End: 2015-03-13Updated: 2017-03-09

Phase 2

A Study of MHAA4549A in Combination With Oseltamivir Versus Oseltamivir in Participants With Severe Influenza A Infection

CompletedNCT02293863

Genentech, Inc.Influenza

Start: 2015-01-14End: 2017-05-23Updated: 2018-06-18

A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults

CompletedNCT02623322

Genentech, Inc.Influenza A

Start: 2016-10-12End: 2017-11-13Updated: 2019-01-08

Related Papers

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of MHAA4549A, a Monoclonal Antibody, plus Oseltamivir in Patients Hospitalized with Severe Influenza A Virus Infection.

2020-06-2334 citations

Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy Volunteers

Antimicrobial Agents and Chemotherapy2016-07-0648 citations